Cargando…

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series

• TP53 variant negative high-grade serous ovarian cancer is rare and can still show p53 abnormal immunohistochemistry. • Diagnostic and therapeutic considerations include pathologic, molecular and clinical domains. • Genetic reassessment through more comprehensive assays should be considered to ensu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasherman, Lawrence, Garg, Swati, Tchrakian, Nairi, Clarke, Blaise, Karakasis, Katherine, Kim, Raymond H., Stockley, Tracy L., Dhani, Neesha, Oza, Amit M., Lheureux, Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910505/ https://www.ncbi.nlm.nih.gov/pubmed/33718561 http://dx.doi.org/10.1016/j.gore.2021.100729

Ejemplares similares

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers
por: Kasherman, Lawrence, et al.
Publicado: (2022)

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
por: Yang, S. Y. Cindy, et al.
Publicado: (2018)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
por: Colombo, Ilaria, et al.
Publicado: (2019)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Ovarian cancer treatment: The end of empiricism?
por: Lheureux, Stephanie, et al.
Publicado: (2015)

Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program
por: Care, Melanie, et al.
Publicado: (2020)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
por: Karakasis, Katherine, et al.
Publicado: (2016)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
por: Chien, Jeremy, et al.
Publicado: (2015)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

Ethical frameworks in clinical research processes during COVID-19: a scoping review
por: Kasherman, Lawrence, et al.
Publicado: (2021)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
por: Sauriol, Alexandre, et al.
Publicado: (2023)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
por: Bhat, Gita, et al.
Publicado: (2020)

Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer
por: Lee, Yeh Chen, et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

Comprehensive genomic profiling of high‐grade serous ovarian carcinoma from Chinese patients identifies co‐occurring mutations in the Ras/Raf pathway with TP53
por: Zhong, Fangfang, et al.
Publicado: (2019)

Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis
por: Paracchini, Lara, et al.
Publicado: (2020)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx)
por: Chaudary, Naz, et al.
Publicado: (2012)

Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
por: McCuaig, Jeanna M., et al.
Publicado: (2022)

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
por: Parkinson, Christine A., et al.
Publicado: (2016)

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
por: Hatano, Yuichiro, et al.
Publicado: (2018)

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
por: Colombo, Ilaria, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Pneumothorax and Pneumatocoele Formation in a Patient with COVID-19: a Case Report
por: Capleton, P., et al.
Publicado: (2021)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

A case report of low grade fetal lung adenocarcinoma with TP53 mutation
por: Wang, Bo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1kdjtk31p2nbvotmlvitluasjn